神經(jīng)嵴細(xì)胞和神經(jīng)嵴病及其致病機(jī)制的研究進(jìn)展

蔣卓遠(yuǎn)，查艷，石小峰，張永彪2,

綜 述

神經(jīng)嵴細(xì)胞和神經(jīng)嵴病及其致病機(jī)制的研究進(jìn)展

蔣卓遠(yuǎn)1，查艷1，石小峰3,4，張永彪2,3,4

1. 北京航空航天大學(xué)生物與醫(yī)學(xué)工程學(xué)院，北京 100000 2. 北京航空航天大學(xué)醫(yī)學(xué)科學(xué)與工程學(xué)院，北京 100000 3. 北京航空航天大學(xué)大數(shù)據(jù)精準(zhǔn)醫(yī)療高精尖創(chuàng)新中心，北京 100000 4. 工信部大數(shù)據(jù)精準(zhǔn)醫(yī)療重點(diǎn)實(shí)驗(yàn)室，北京 100000

神經(jīng)嵴細(xì)胞(neural crest cells，NCCs)是一類(lèi)脊椎動(dòng)物特有的可遷移的多能干細(xì)胞，其可分化為軟骨細(xì)胞、神經(jīng)元和黑色素細(xì)胞等多種類(lèi)型細(xì)胞。NCCs的形成、遷移和分化受到嚴(yán)格調(diào)控，任何擾亂NCCs發(fā)育的因素都可導(dǎo)致胚胎發(fā)育畸形。由神經(jīng)嵴細(xì)胞發(fā)育異常所導(dǎo)致的一系列疾病統(tǒng)稱(chēng)為神經(jīng)嵴病(neurocristopathies，NCPs)。NCPs種類(lèi)繁多且表型復(fù)雜，可累及人體多個(gè)部位(顱面部、心臟、腸胃和皮膚等)，嚴(yán)重危害患者的身體機(jī)能和心理健康。NCPs占所有出生缺陷患兒的1/3，遺傳因素是導(dǎo)致NCPs的主要風(fēng)險(xiǎn)因素，但環(huán)境風(fēng)險(xiǎn)因子以及基因–環(huán)境交互作用異常也可導(dǎo)致NCPs。本文對(duì)神經(jīng)嵴細(xì)胞和神經(jīng)嵴病及其致病機(jī)制進(jìn)行綜述，為系統(tǒng)認(rèn)知神經(jīng)嵴細(xì)胞發(fā)育以及神經(jīng)嵴病提供參考，為了解神經(jīng)嵴病的病因以及開(kāi)展有效防控提供科學(xué)支撐。

神經(jīng)嵴細(xì)胞；神經(jīng)嵴??；基因調(diào)控網(wǎng)絡(luò)；風(fēng)險(xiǎn)因素；發(fā)病機(jī)制

神經(jīng)嵴細(xì)胞(neural crest cells，NCCs)是脊椎動(dòng)物胚胎發(fā)育早期的一種具備全胚胎遷移性的全能性干細(xì)胞[1]。NCCs經(jīng)過(guò)了從軀干向頭部逐步特化的過(guò)程，對(duì)脊椎動(dòng)物頭顱的演化起到至關(guān)重要的作用[2,3]。NCCs賦予了脊椎動(dòng)物高級(jí)的感官系統(tǒng)、復(fù)雜且精細(xì)的神經(jīng)系統(tǒng)以及強(qiáng)有力的掠食器官，支持脊椎動(dòng)物從被動(dòng)的濾食行為演化到主動(dòng)捕食的生活方式[4]。NCCs起源于背側(cè)外胚層的神經(jīng)板邊界，神經(jīng)褶皺的融合誘導(dǎo)了神經(jīng)管的閉合以及NCCs的形成。隨后，神經(jīng)嵴細(xì)胞會(huì)有序地從胚胎背側(cè)向腹側(cè)遷移，在遷移過(guò)程中以二元命運(yùn)決定方式分化成為祖細(xì)胞和間質(zhì)細(xì)胞，進(jìn)而繼續(xù)二元命運(yùn)決定，分化為軟骨細(xì)胞、色素細(xì)胞、平滑肌細(xì)胞和神經(jīng)元等[5,6]。除此之外，遷移的NCCs還在胚胎發(fā)育早期替代未發(fā)育的吞噬類(lèi)細(xì)胞發(fā)揮死細(xì)胞的清除功能[7]。NCCs雖然來(lái)自外胚層，但其仍具備分化為中胚層和內(nèi)胚層的能力，因此，有學(xué)者將神經(jīng)嵴稱(chēng)為“第四胚層”，甚至其多能性特征高于其他三個(gè)胚層[8]。

NCCs賦予脊椎動(dòng)物演化優(yōu)勢(shì)的同時(shí)，也引入了發(fā)育畸形風(fēng)險(xiǎn)。NCCs的發(fā)育過(guò)程始終受基因嚴(yán)格調(diào)控，任何異常調(diào)控都將擾亂NCCs正常發(fā)育，進(jìn)而導(dǎo)致胚胎發(fā)育畸形。1974年，Bolande等[9]統(tǒng)梳理了NCCs衍生物異常發(fā)育的系列疾病，并統(tǒng)稱(chēng)為神經(jīng)嵴病(neurocristopathies，NCPs)。已知的顱面部發(fā)育缺陷大多數(shù)和神經(jīng)嵴細(xì)胞發(fā)育相關(guān)，而顱面部出生缺陷患者幾乎占所有人類(lèi)出生缺陷的1/3[10]，他們臨床癥狀復(fù)雜，病因大多未知，分類(lèi)較為混亂。導(dǎo)致該現(xiàn)狀的主要原因有：(1)NCPs種類(lèi)繁多，多為散發(fā)罕見(jiàn)病例，樣本收集困難，導(dǎo)致難以進(jìn)行系統(tǒng)研究；(2)不同NCPs臨床特征紛亂交疊，NCPs的病例癥狀多樣、表型冗雜交疊，目前未形成系統(tǒng)有效的分類(lèi)體系；(3)NCPs病因缺乏系統(tǒng)揭示，NCPs基本都是獨(dú)立研究，如典型代表——唇腭裂和先天性巨結(jié)腸(Hirschsprung)，但在NCCs層面系統(tǒng)的研究各類(lèi)NCPs的工作仍未開(kāi)展[11]。本文依據(jù)NCPs的受累器官對(duì)其進(jìn)行系統(tǒng)分類(lèi)，然后以NCCs的發(fā)育為線(xiàn)索，對(duì)NCPs的病因進(jìn)行梳理，總結(jié)了NCCs發(fā)育異常導(dǎo)致各類(lèi)NCPs的機(jī)制。

1 神經(jīng)嵴細(xì)胞

1.1 NCCs的形成

NCCs來(lái)源于神經(jīng)板邊界(neural plate border，NPB)內(nèi)的神經(jīng)嵴祖細(xì)胞(圖1)。在人類(lèi)早期胚胎發(fā)育過(guò)程中，神經(jīng)嵴祖細(xì)胞可誘導(dǎo)促使神經(jīng)板兩側(cè)的NPB隆起，形成神經(jīng)褶皺，隨后隆起的神經(jīng)褶皺融合形成神經(jīng)管，神經(jīng)嵴祖細(xì)胞聚集于神經(jīng)管背側(cè)區(qū)域，以等待調(diào)控因子提供特化(specification)信號(hào)[1]。

NCCs的形成分為誘導(dǎo)(induction)、特化(specification)和預(yù)遷移(pre-migration)三個(gè)階段(圖1)。小鼠模型研究揭示NCCs形成過(guò)程由多個(gè)調(diào)控通路參與，包括骨形態(tài)發(fā)生蛋白(Bmp)信號(hào)通路、Wnt信號(hào)通路、成纖維細(xì)胞生長(zhǎng)因子(Fgf)信號(hào)通路和Notch信號(hào)通路[1]。研究發(fā)現(xiàn)，Bmp信號(hào)在NCCs誘導(dǎo)早期開(kāi)始發(fā)揮作用，然后激活Wnt信號(hào)在NCCs的特化階段發(fā)揮調(diào)控活性，他們均對(duì)該階段NCCs數(shù)量的維持起關(guān)鍵作用[12]。Fgf信號(hào)主要在誘導(dǎo)過(guò)程中發(fā)揮作用，F(xiàn)gf8信號(hào)的中斷阻止了NPB基因的表達(dá)[13]。

1.2 NCCs的遷移

NCCs的遷移始于神經(jīng)管閉合，遷移之初，NCCs經(jīng)上皮–間充質(zhì)轉(zhuǎn)化(epithelial-mesenchymal transition，EMT)過(guò)程從神經(jīng)管背側(cè)剝離，然后開(kāi)始遷移。NCCs的EMT過(guò)程是從形成態(tài)向遷移態(tài)的轉(zhuǎn)換，轉(zhuǎn)換后的細(xì)胞命運(yùn)由一系列調(diào)控因子決定。Soldatov等[6]發(fā)現(xiàn)在NCCs的命運(yùn)決定在遷移時(shí)就已發(fā)生，NCCs遷移前階段就分化為兩個(gè)不同的亞群：第一是最早的EMT前群，它們由未分層(delamination)的NCCs組成；第二是分層的細(xì)胞亞群，其特征在于EMT的關(guān)鍵基因的激活和的沉默，該亞群細(xì)胞還被一系列基因的連續(xù)瞬時(shí)調(diào)控，如、、和。之后細(xì)胞命運(yùn)決定具體表現(xiàn)為一系列連續(xù)的二元甚至多元決定過(guò)程，該過(guò)程首先表現(xiàn)為NCCs向感覺(jué)類(lèi)的神經(jīng)膠質(zhì)細(xì)胞和其他過(guò)渡類(lèi)型細(xì)胞的身份轉(zhuǎn)換，隨后過(guò)渡類(lèi)型細(xì)胞再向自主神經(jīng)細(xì)胞和間質(zhì)細(xì)胞身份轉(zhuǎn)化的二元命運(yùn)決定過(guò)程，這兩類(lèi)細(xì)胞繼續(xù)后續(xù)的命運(yùn)決定過(guò)程，直至分化為最終細(xì)胞類(lèi)型。

圖1 NCCs的發(fā)育過(guò)程受信號(hào)因子的嚴(yán)格調(diào)控

NCCs的形成始于神經(jīng)板邊界，主要由Wnts、Bmps、Fgfs和Notchs信號(hào)調(diào)節(jié)。在神經(jīng)管形成早期，神經(jīng)嵴祖細(xì)胞位于NPB中，其誘導(dǎo)神經(jīng)板(neural plate，NP)兩側(cè)的NPB隆起形成神經(jīng)褶皺，兩側(cè)的神經(jīng)褶皺融合形成神經(jīng)管后，NCCs便開(kāi)始誘導(dǎo)–特化–預(yù)遷移過(guò)程。在大多數(shù)脊椎動(dòng)物中，NCCs的分層及遷移始于神經(jīng)管閉合，但該過(guò)程也可早于神經(jīng)管閉合，比如小鼠的NCCs分層在神經(jīng)管未閉合時(shí)即發(fā)生。NCCs：神經(jīng)嵴細(xì)胞；NPB：神經(jīng)板邊界；NF：神經(jīng)褶皺；SO：體節(jié)；NT：神經(jīng)管；NO：脊索。

根據(jù)NCCs的形成位置和遷移路線(xiàn)，可將其分為四種類(lèi)型：顱、軀干、迷走和骶NCCs，遷移后在胚胎的各部位分化成多種功能細(xì)胞(圖2：A和B)。顱NCCs從神經(jīng)管背側(cè)遷移出來(lái)后，將分裂成三束分散(discrete streams)的細(xì)胞流：遷移至中、前腦的背側(cè)細(xì)胞流，遷移入鰓弓的腹側(cè)細(xì)胞流以及從后腦向其他部位遷移的細(xì)胞流[14]。軀干NCCs從第7～28體節(jié)的神經(jīng)管向外遷移的路線(xiàn)有兩條：一條途徑沿背外側(cè)呈連續(xù)狀遷移(continuous wave)，主要發(fā)育為色素細(xì)胞；另一條途徑沿腹內(nèi)側(cè)呈分段式(segmented manner)遷移，主要發(fā)育為膠質(zhì)和神經(jīng)元前體[15]。迷走NCCs從菱形腦節(jié)4～7產(chǎn)生后主要遷移到心臟，同時(shí)也像骶NCCs遷移到腸道定植，這個(gè)是NCCs最長(zhǎng)的一條遷移路線(xiàn)[16]。神經(jīng)嵴細(xì)胞的遷移受到了多種信號(hào)的嚴(yán)格調(diào)控[17](圖2C)，包括局部抑制劑，誘導(dǎo)劑和細(xì)胞粘附分子，如Snails可直接抑制細(xì)胞粘附分子E-cadherin，促進(jìn)細(xì)胞遷移，Eph/ephrin、內(nèi)皮素和Slit/Robo信號(hào)決定了NCCs的背外側(cè)和腹內(nèi)側(cè)遷移路徑的選擇。

最新研究發(fā)現(xiàn)NCCs的遷移行為還和外周環(huán)境存在交互，該過(guò)程賦予NCCs在早期胚胎發(fā)育中發(fā)揮特殊的功能：在特異吞噬細(xì)胞出現(xiàn)之前，遷移的NCCs被證實(shí)能在神經(jīng)系統(tǒng)中承擔(dān)吞噬細(xì)胞碎片的功能。該吞噬過(guò)程與巨噬細(xì)胞吞噬相似，均由白細(xì)胞介素-1所介導(dǎo)[7]?，F(xiàn)階段，NCCs在遷移過(guò)程中的時(shí)空調(diào)控網(wǎng)絡(luò)以及與周?chē)?xì)胞的互作關(guān)系還亟待深入研究，明晰其遷移轉(zhuǎn)折點(diǎn)的決策機(jī)制也將成為后續(xù)研究熱點(diǎn)。

1.3 NCCs的分化

NCCs最終分化成何種細(xì)胞和解剖結(jié)構(gòu)類(lèi)型，主要取決于終點(diǎn)微環(huán)境。當(dāng)NCCs遇到血管或細(xì)胞簇

等提供的終止遷移信號(hào)時(shí)，便開(kāi)始分化[11]。顱神經(jīng)嵴細(xì)胞(cranial neural crest cells，CNCCs)最終遷移至頭部和咽弓，參與顱面部的骨骼，皮膚，神經(jīng)和肌肉的形成。其他部位的NCCs最終分化三個(gè)為：迷走神經(jīng)嵴細(xì)胞參與主動(dòng)脈肺隔、心神經(jīng)節(jié)和腸神經(jīng)節(jié)的形成；軀干神經(jīng)嵴細(xì)胞發(fā)育為黑色素細(xì)胞、神經(jīng)元、神經(jīng)膠質(zhì)和施旺細(xì)胞；骶神經(jīng)嵴細(xì)胞分化成交感神經(jīng)節(jié)和腸神經(jīng)節(jié)[11,18](圖2：B和D)。

2 神經(jīng)嵴病

2.1 神經(jīng)嵴病的分類(lèi)

1974年，Bolande等[9]將由NCCs及其衍生物異常發(fā)育引起的一系列疾病統(tǒng)稱(chēng)為NCPs，如Treacher Collin綜合征、唇腭裂、Waardenburg綜合征、先天性巨結(jié)腸。隨著研究的深入，那些由于核糖體或纖毛等具體結(jié)構(gòu)發(fā)育異常進(jìn)而導(dǎo)致NCCs發(fā)育異常的疾病也被列入NCPs范疇，如核糖體病、纖毛病等。然而由于神經(jīng)嵴細(xì)胞參與了機(jī)體大量細(xì)胞和器官的發(fā)育，從而導(dǎo)致神經(jīng)嵴病數(shù)量眾多，加上NCPs表型多樣以及病因認(rèn)知不足導(dǎo)致神經(jīng)嵴病未被系統(tǒng)梳理。1977年，Reed等[19]依照是否伴發(fā)腫瘤將NCPs劃分為發(fā)育異常(dysplasias)、腫瘤(neoplasms)以及畸形和腫瘤并存的三種類(lèi)型。2018年，Vega-Lopea等[11]按照神經(jīng)嵴細(xì)胞的來(lái)源將神經(jīng)嵴病分為顱神經(jīng)嵴病、軀干神經(jīng)嵴病、迷走神經(jīng)嵴病和骶神經(jīng)嵴病。但上述分類(lèi)方法過(guò)于簡(jiǎn)單，不利于對(duì)NCPs的系統(tǒng)認(rèn)知。本文將按照神經(jīng)嵴病的主要累及器官，對(duì)已知的神經(jīng)嵴病進(jìn)行分類(lèi)，同時(shí)將和NCCs相關(guān)的腫瘤單獨(dú)舉出為一類(lèi)(圖3)。

圖2 NCCs的遷移和分化

A：NCCs在胚胎中的遷移路徑。NCCs分為顱神經(jīng)嵴、迷走神經(jīng)嵴、軀干神經(jīng)嵴和骶神經(jīng)嵴四個(gè)類(lèi)型。箭頭表示NCCs的遷移流。B：NCCs可分化的組成機(jī)體的主要細(xì)胞類(lèi)型。C：NCCs遷移過(guò)程的調(diào)控因子和信號(hào)通路。D：調(diào)控NCCs分化為各種細(xì)胞類(lèi)型的關(guān)鍵調(diào)控信號(hào)。Ⅰ、Ⅱ：第一/二咽弓；OV：聽(tīng)囊。

2.2 神經(jīng)嵴病的典型病癥

神經(jīng)嵴病可發(fā)生在全身多個(gè)部位，或累及單個(gè)器官，或同時(shí)累及多個(gè)器官，形成復(fù)雜的神經(jīng)嵴疾病。本文根據(jù)人體的解剖結(jié)構(gòu)進(jìn)行劃分，總結(jié)了NCPs的典型表型，列舉了NCPs引起的顱面、臟器、四肢、皮膚及全身發(fā)育的異常[20](表1)。顱面部畸形是最常見(jiàn)的典型特征，通常包括上、下頜不完全發(fā)育，牙齒形態(tài)異常，進(jìn)食和說(shuō)話(huà)困難。下頜的嚴(yán)重發(fā)育不良會(huì)使嬰幼兒的氣管受到壓迫，氣管狹窄，從而影響呼吸，甚至導(dǎo)致死亡。部分患者眼睛歪斜、睫毛稀疏、眼睛色素異常，導(dǎo)致視力下降。耳朵發(fā)育異常也是多種NCPs的典型特征，如外耳發(fā)育不全或缺失(小耳或無(wú)耳)、耳道閉鎖、聽(tīng)力喪失等[21]。

圖3 NCCs發(fā)育異常導(dǎo)致的神經(jīng)嵴病所累及的人體器官及系統(tǒng)

按照神經(jīng)嵴病的主要累及器官，對(duì)已知的神經(jīng)嵴病進(jìn)行分類(lèi)。如唇腭裂、半側(cè)顏面短小等都是具有典型顱面部癥狀的神經(jīng)嵴病，先天性巨結(jié)腸是典型的消化道NCP。CDHS：顱面–耳聾–手綜合征(craniofacial-deafness-hand syndrome)；SHFM4：裂手/裂腳畸形4型(split-hand/split-foot malformation type 4)；LMS：四肢-乳腺綜合征(limb-mammary syndrome)；TDO：毛齒骨綜合征(tricho-dento-osseous syndrome)；VHL：Von Hippel-Lindau綜合征(Von Hippel-Lindau syndrome)。

2.3 神經(jīng)嵴病流行病學(xué)分析

神經(jīng)嵴病占所有先天性出生缺陷患兒的1/3[10]。據(jù)統(tǒng)計(jì)，頜面部第一高發(fā)出生缺陷——唇腭裂發(fā)病率為1/500～1/1000[27]，而頜面部受累器官最多的半側(cè)顏面短小畸形的發(fā)生率在1/5600～1/6550[22]。1歲以下嬰兒最常見(jiàn)的癌癥——神經(jīng)母細(xì)胞瘤發(fā)病率為每1/10萬(wàn)新生兒。消化道典型的神經(jīng)嵴病——先天性巨結(jié)腸(Hirschsprung disease，HSCR)的發(fā)病率約為1/5000新生兒[11]。然而，神經(jīng)嵴病的發(fā)病率很可能被低估了，原因在于醫(yī)生對(duì)NCPs的本身及其變異性的認(rèn)識(shí)不足，輕微表型畸形得不到重視，以及疾病無(wú)法得到充分且精確診斷。NCPs發(fā)病部位的一個(gè)典型特征是存在機(jī)體的不對(duì)稱(chēng)性，表現(xiàn)為大部分受累器官僅出現(xiàn)在單側(cè)(表2)。

2.4 神經(jīng)嵴病的防治

當(dāng)前對(duì)于遺傳疾病，以防控為主，診療為輔。由于大量神經(jīng)嵴病患者頜面部畸形明顯，不僅給患者造成身心傷害，后期的矯正性治療還將給家庭和社會(huì)帶來(lái)巨大經(jīng)濟(jì)壓力。將防控關(guān)口前移是出生缺陷防治的重要方向，對(duì)存在遺傳風(fēng)險(xiǎn)家族史的孕婦采取產(chǎn)前檢測(cè)可有效避免畸形胎兒出生。而在孕期進(jìn)行適當(dāng)?shù)姆揽毓芾?，如補(bǔ)充葉酸，避免暴露在致畸劑，如酒精、尼古丁、維甲酸、甲醛等是NCPs防控的較優(yōu)策略。

表1 神經(jīng)嵴病發(fā)病部位和臨床表型

TCS：Treacher Collin綜合征(Treacher Collins syndrome)；CS：顱縫早閉(craniosynostosis)；HFM：半側(cè)顏面短小畸形(hemifacial microsomia)；DBA：先天性再生障礙性貧血(diamond blackfan anemia)；CADSIL：大腦常染色體顯性動(dòng)脈病變伴皮層下梗死和白質(zhì)腦病(cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)；PHACES：后窩畸形–血管瘤–動(dòng)脈異常–心臟缺陷–眼睛異常–胸骨裂和臍上中縫(posterior fossa malformations–hemangiomas–arterial anomalies–cardiac defects–eye abnormalities–sternal cleft and supraumbilical raphe)；HSCR：先天巨結(jié)腸(Hirschsprung disease)；AAA：三聯(lián)A綜合征(achalasia- addisonianism-alacrima)：CCHS：先天性中樞性通氣不足癥候群(congenital central hypoventilation)；NAS：Nager 綜合征(nager syndrome)；NS：努南綜合征(noonan syndrome)；OCA：眼–皮膚白化病(oculocutaneous albinism)；HED：少汗性外胚層發(fā)育不良(hypohidrotic ectodermal dysplasia；CPHD：垂體激素缺乏癥(combined pituitary hormone deficiency)；GDFD：發(fā)育遲緩，面部畸形(growth retardation, developmental delay, and facial dysmorphism)。

表2 代表性神經(jīng)嵴病的發(fā)生率及患側(cè)發(fā)生比例

體表畸形的神經(jīng)嵴病的治療主要運(yùn)用手術(shù)矯正，如唇腭裂、小耳畸形等。NCPs相關(guān)腫瘤的治療也已實(shí)現(xiàn)靶向藥物治療和低劑量化療，如神經(jīng)母細(xì)胞瘤。體外協(xié)助治療也是行之有效的手段，對(duì)于聽(tīng)力喪失和呼吸困難的患者采取助聽(tīng)器和通氣治療，可極大改善患者生活質(zhì)量甚至挽救患者生命。隨著科技的不斷進(jìn)步，基因治療和干細(xì)胞治療未來(lái)可期：干預(yù)基因進(jìn)而矯正NCCs在TCS患者中的異常發(fā)育已經(jīng)在小鼠模型上獲得成功[31]；母體抗氧化劑修復(fù)DNA損傷防止NCCs細(xì)胞凋亡可能成為預(yù)防神經(jīng)嵴病的有效手段[32]；利用干細(xì)胞再生技術(shù)實(shí)現(xiàn)受損或畸形的組織修復(fù)將是未來(lái)NCPs治療研究的重心。

3 神經(jīng)嵴病的病因?qū)W

眾多轉(zhuǎn)錄因子和信號(hào)分子協(xié)同調(diào)控了神經(jīng)嵴細(xì)胞的復(fù)雜發(fā)育過(guò)程。在該過(guò)程中，任何調(diào)控異常都會(huì)擾亂NCCs的形成、遷移和分化，導(dǎo)致NCPs的產(chǎn)生?，F(xiàn)在公認(rèn)的神經(jīng)嵴病的致病因素是：NCCs基因調(diào)控網(wǎng)絡(luò)(genetic regulation network，GRN)內(nèi)的基因突變、表觀(guān)修飾異常以及環(huán)境致畸因素。由于NCPs種類(lèi)眾多，GRN調(diào)控信號(hào)復(fù)雜，導(dǎo)致GRN的基因突變、NCCs發(fā)育過(guò)程和神經(jīng)嵴病三者的關(guān)系難以系統(tǒng)總結(jié)。下面根據(jù)NCCs發(fā)育過(guò)程中基因發(fā)揮調(diào)控活性的時(shí)序(附圖1)，梳理了神經(jīng)嵴病的發(fā)病機(jī)制。

3.1 基因調(diào)控網(wǎng)絡(luò)異常

3.1.1 NCCs形成異常所致的神經(jīng)嵴病

NCCs的形成是一個(gè)多步驟的過(guò)程。在NCCs形成前后，、和等神經(jīng)板邊界調(diào)控基因的開(kāi)始表達(dá)，緊隨其后的是更具特異性的NCCs調(diào)控基因，包括、和等[33,34]。其中作為轉(zhuǎn)錄因子的SOX9、PAX3、TFAP2A、FOXD3等信號(hào)異常，會(huì)影響NCCs的形成過(guò)程，導(dǎo)致細(xì)胞分裂和細(xì)胞的凋亡異常(表3)。在神經(jīng)嵴細(xì)胞的生長(zhǎng)和增殖過(guò)程中，核糖體扮演著重要的角色。核糖體會(huì)將信使RNA(mRNA)翻譯成氨基酸序列，參與細(xì)胞內(nèi)蛋白的合成。本文以NCCs形成異常所導(dǎo)致的典型神經(jīng)嵴病——核糖體病為例，闡述其發(fā)病機(jī)制。

核糖體的形成過(guò)程如下：在多種轉(zhuǎn)錄因子的調(diào)控下，首先核糖體DNA(rDNA)會(huì)被轉(zhuǎn)錄成pre- rRNA。pre-rRNA生成后，會(huì)生成一個(gè)中間過(guò)渡的轉(zhuǎn)錄本，然后再被加工成成熟的rRNA。RPs與rRNA組裝成核糖體的小亞基(40S)和大亞基(60S)，最后會(huì)被運(yùn)輸?shù)郊?xì)胞質(zhì)中進(jìn)一步形成成熟的核糖體。該過(guò)程中，某些基因的突變會(huì)造成核糖體的合成異常導(dǎo)致NCPs，其致病機(jī)制是因核糖體的合成不足，最終導(dǎo)致NCCs分裂異?；蚣?xì)胞凋亡程序失控，導(dǎo)致NCCs形成不足[35]。由于相關(guān)基因突變導(dǎo)致核糖體合成異常而影響NCCs形成所產(chǎn)生的NCPs，稱(chēng)為核糖體病，它是NCPs的一個(gè)重要的亞型[36](圖4)。

3.1.2 NCCs遷移異常所致的神經(jīng)嵴病

神經(jīng)嵴細(xì)胞的遷移過(guò)程由細(xì)胞內(nèi)的自主信號(hào)以及在遷移過(guò)程中與細(xì)胞相互作用的周?chē)h(huán)境共同協(xié)調(diào)調(diào)控[14,17,56,57]。在分層階段，Snails轉(zhuǎn)錄因子家族發(fā)揮了主要的作用。、等基因也是NCCs遷移所必需的，其突變被證實(shí)會(huì)影響哺乳動(dòng)物NCCs的分層和遷移。斑駁病、家族性自主神經(jīng)障礙(FD)和II型瓦登伯格綜合征(WSⅡ)等都是典型的由于NCCs遷移異常所導(dǎo)致的神經(jīng)嵴病(表3)[31～33]。

迷走和骶NCCs會(huì)遷移到腸道，在腸道形成腸道神經(jīng)元，組成腸道神經(jīng)系統(tǒng)(enteric nervous system，ENS)。許多營(yíng)養(yǎng)因子、細(xì)胞表面受體、轉(zhuǎn)錄因子和信號(hào)分子參與了此遷移活動(dòng)，如Eph/Ephrin、BMP、RET信號(hào)等。其中RET是一種跨膜蛋白，受到BMP信號(hào)調(diào)控，參與ENS的存活，增殖，遷移和分化過(guò)程。EDNRB與RET信號(hào)協(xié)同激活MAKP和PI3K通路下游信號(hào)和調(diào)控基因，如和基因突變會(huì)影響ENS的發(fā)育，導(dǎo)致先天性巨結(jié)腸癥。先天性巨結(jié)腸的主要病因是由于ENS前體細(xì)胞不能定植胎兒腸遠(yuǎn)端，導(dǎo)致腸道神經(jīng)元缺失，出現(xiàn)腸梗阻(圖5)。

表3 基因調(diào)控網(wǎng)絡(luò)異常導(dǎo)致的神經(jīng)嵴病

PA1/2：第1/2鰓弓；PRS：皮埃爾·羅賓序列(Pierre Robin sequence)；WS：瓦登伯格綜合征(Waardenburg syndrome)；CDHS：顱面–耳聾–手綜合征(craniofacial-deafness-hand syndrome)；BOFS：鰓–眼–面部綜合征(branchio-oculo-facial syndrome)；TCS：Treacher Collins綜合征(Treacher Collins syndrome)；DBA：先天性再生障礙性貧血(diamond blackfan anemia)；MS：米勒綜合征(Miller syndrome)；NS：努南綜合征(noonan syndrome)；HSCR：先天性巨結(jié)腸癥(Hirschsprung disease)；BBB：Opitz G/BBB綜合征(opitz g/bbb syndrome)；FD：家族性自主神經(jīng)障礙(familial dysautonomia)；NB：成神經(jīng)細(xì)胞瘤(neuroblastoma)；Tietz：Tietz綜合征(Tietz syndrome)；CADSIL：常染色體顯性遺傳病合并皮質(zhì)下梗死和白質(zhì)腦病(cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)；HH：性腺功能減退癥(hypogonadotropic hypogonadism)；KS：Kallmann綜合征(Kallmann Syndrome)；CPHD：合并垂體激素缺乏(combined pituitary hormone deficiency)；AEC：AEC綜合征(aec syndrome)；LMS：四肢–乳腺綜合征(limb-mammary syndrome)。

3.1.3 NCCs分化異常所致的神經(jīng)嵴病

神經(jīng)嵴細(xì)胞的分化是細(xì)胞命運(yùn)決定的結(jié)果，一些轉(zhuǎn)錄因子定義了NCCs的初始分裂狀態(tài)，并賦予了它向不同的譜系分化的潛力。在NCCs遷移過(guò)程中，和就已經(jīng)參與了NCCs的命運(yùn)決定：在NCCs發(fā)育過(guò)程的初期開(kāi)始表達(dá)，它決定了NCCs向間充質(zhì)細(xì)胞(骨、軟骨和結(jié)締組織)分化的潛能，而則定義了早期的感覺(jué)神經(jīng)NCCs祖細(xì)胞，將它們和色素NCCs祖細(xì)胞進(jìn)行區(qū)分[6]。之后再通過(guò)各類(lèi)特異性因子調(diào)控，NCCs得以分化形成不同類(lèi)型的細(xì)胞，如PHOX2B與神經(jīng)元的形成相關(guān)、MITF與黑色素細(xì)胞發(fā)育相關(guān)、FGF9與嗅神經(jīng)發(fā)育相關(guān)和NOTCH3與血管平滑肌細(xì)胞相關(guān)(表3)。

黑色素細(xì)胞是NCCs的重要衍生細(xì)胞之一，參與了皮膚色素、視網(wǎng)膜色素的形成，還參與內(nèi)耳的發(fā)育，影響胎兒聽(tīng)力。編碼黑素細(xì)胞誘導(dǎo)轉(zhuǎn)錄因子MITF，控制黑色素細(xì)胞發(fā)育及其功能。MITF還受到其他NCCs特異基因的調(diào)控：PAX3與SOX10能反式激活其啟動(dòng)子，協(xié)同上調(diào)的表達(dá)[58]。腸道神經(jīng)元分化的調(diào)控信號(hào)和黑色素細(xì)胞的調(diào)控網(wǎng)絡(luò)存在交互作用，、和除了在NCCs來(lái)源的黑色素細(xì)胞表達(dá)外，也是腸神經(jīng)元細(xì)胞增殖、遷移和生存的關(guān)鍵基因。以上幾種基因中的任何突變都會(huì)導(dǎo)致皮膚黑色素細(xì)胞和腸道中神經(jīng)元的缺失，引起WS和斑駁病(圖6)。

圖4 核糖體的合成異常導(dǎo)致的神經(jīng)嵴病的發(fā)病機(jī)制

與NCPs相關(guān)的基因突變會(huì)導(dǎo)致核糖體的合成異常，造成顱面部畸形。RNA聚合酶I和III參與rDNA轉(zhuǎn)錄，Treacher Collin綜合征中、和的突變會(huì)破壞轉(zhuǎn)錄復(fù)合物的形成，影響rRNA的產(chǎn)生。尿嘧啶也參與rRNA的合成，Miller綜合征中的突變干擾尿嘧啶的合成。在RNA聚合酶I和III合成pre-rRNA后，基因(、等)突變破壞核糖體的合成，導(dǎo)致DBA。rDNA：核糖體DNA；pre-rRNA：前核糖體RNA。

圖5 周?chē)窠?jīng)細(xì)胞異常神經(jīng)嵴病的發(fā)病機(jī)制

RET是一種跨膜酪氨酸蛋白，RET信號(hào)功能涉及ENS的存活、增殖、遷移和分化。RET也受到BMP信號(hào)調(diào)控，影響ENS的遷移。RET和EDNRB激活MAKP PI3K通路下游信號(hào)：與腸神經(jīng)發(fā)育相關(guān)的PAX3、SOX10和PHOX2B協(xié)同激活RET轉(zhuǎn)錄。和突變也將影響ENS的發(fā)育，導(dǎo)致先天性巨結(jié)腸。Hirschsprung disease：先天巨結(jié)腸癥；Mowat-Wilson syndrome：Mowat-Wilson綜合征。

3.2 表觀(guān)遺傳因素

表觀(guān)遺傳學(xué)即DNA和RNA等大分子的修飾，在NCCs的發(fā)育中也起著重要的調(diào)控作用。表觀(guān)遺傳機(jī)制是微調(diào)基因表達(dá)和細(xì)胞分化的關(guān)鍵因素，它將影響基因表達(dá)并傳遞給后代。探索NCCs的表觀(guān)遺傳學(xué)機(jī)制，有助于了解NCPs的病因[59]。根據(jù)表觀(guān)修飾類(lèi)型的不同，表4總結(jié)了涉及突變影響的修飾基團(tuán)、靶基因以及NCCs發(fā)育階段，納入了最新發(fā)現(xiàn)的microRNA的調(diào)控異常導(dǎo)致的NCPs，梳理了不同表觀(guān)遺傳修飾異常所導(dǎo)致的神經(jīng)嵴病。

3.3 環(huán)境因素

神經(jīng)嵴病的病因可歸于內(nèi)在遺傳因素和外在環(huán)境因素的異常導(dǎo)致胚胎發(fā)育畸形[80]。研究發(fā)現(xiàn)孕婦能通過(guò)食物、飲用水、藥物和空氣傳播以及皮膚接觸到有害的環(huán)境因素，這些都將影響NCCs的發(fā)育過(guò)程。據(jù)估計(jì)，大約10%～15%的先天出生類(lèi)缺陷是由于環(huán)境因素(致畸劑)對(duì)胚胎發(fā)育的不利影響所導(dǎo)致的[81]。另外，環(huán)境危險(xiǎn)因素還可能通過(guò)與遺傳因素的相互作用影響NCCs的發(fā)育，如Xu等[22]通過(guò)基因–環(huán)境交互作用檢驗(yàn)研究半側(cè)顏面短小(hemifacial microsomia，HFM)風(fēng)險(xiǎn)因素時(shí)，發(fā)現(xiàn)妊娠期父親吸煙與HFM相關(guān)SNP(單核苷酸多態(tài)性，single nucleotide polymorphism)存在顯著交互作用，提示吸煙暴露會(huì)增加CFM風(fēng)險(xiǎn)。另外大量的分子、藥物和致畸劑或胎兒毒性物質(zhì)也會(huì)影響NCCs的發(fā)育：高糖、維甲酸、四氫大麻酚、可卡因、嗎啡、氯胺酮、血管緊張素轉(zhuǎn)換酶抑制劑、波生坦、氯霉素、卡馬西平、氟康唑、草甘膦除草劑、鋰化合物、甲氨蝶呤、苯巴比妥、他莫昔芬、沙利度胺、甲苯、曲妥珠單抗、維甲酸、丙戊酸等[81]。下面簡(jiǎn)要描述一些典型的導(dǎo)致NCCs發(fā)育異常的環(huán)境因素的致畸源作為參考。

圖6 黑色素細(xì)胞發(fā)育異常神經(jīng)嵴病

EDNRB和KIT傳導(dǎo)的信號(hào)激活MAPK通路，之后作用于MITF的M亞型，該亞型只在黑色素細(xì)胞譜系中表達(dá)?？刂坪谏丶?xì)胞的發(fā)育和細(xì)胞功能。PAX3與SOX10反式激活MITF啟動(dòng)子，協(xié)同上調(diào)MITF的表達(dá)。作為MITF的一種效應(yīng)基因，是Kit和E-鈣粘蛋白基因的轉(zhuǎn)錄抑制因子，影響黑色素細(xì)胞的發(fā)育。Piebaldism：斑駁??；Tietz：Tietz綜合征(Tietz syndrome)；WS：Waardenburg綜合征(Waardenburg syndrome)。

表4 表觀(guān)遺傳修飾對(duì)神經(jīng)嵴發(fā)育的調(diào)控

BDMR：非綜合征性口唇裂及短趾性智力發(fā)育遲滯綜合征(non-syndromic oral clefts and brachydac-tyly mental retardation syndrome)；BOFS：鰓–眼–面部綜合征(branchio-oculo-facial syndrome)；HSCR：先天性巨結(jié)腸癥(Hirschsprung disease)。

3.3.1 乙醇：胎兒酒精譜系障礙(fetal alcohol spectrum disorder，F(xiàn)ASD)

懷孕期間飲酒現(xiàn)在被認(rèn)為是一種潛在的致畸風(fēng)險(xiǎn)，可能導(dǎo)致以眼瞼裂隙短上唇延長(zhǎng)和發(fā)育不全為特征的胎兒酒精譜系障礙[82]。懷孕期間過(guò)度接觸酒精會(huì)導(dǎo)致胎兒顱面畸形，占所有酒精導(dǎo)致的出生缺陷的1/3。研究發(fā)現(xiàn)將早期胚胎暴露在乙醇中，發(fā)現(xiàn)細(xì)胞內(nèi)的酶活性降低，核糖體凋亡，并破壞了神經(jīng)的發(fā)育，其中包括神經(jīng)元存活、增殖、細(xì)胞遷移和突觸的形成都受到了影響[83]。取雞胚胎研究的額外證據(jù)表明，酒精能抑制Wnt和Shh信號(hào)，從而改變NCCs的遷移和存活[84]。最終導(dǎo)致顱和心臟NCCs數(shù)量減少，遷移不流足，引發(fā)顱面部畸形甚至先天性心臟病[81]。

3.3.2 維甲酸(retinoic acid，RA)

維生素A胚胎病是一種由子宮內(nèi)過(guò)度暴露于維甲酸引起的NCP，以小耳朵、頜骨發(fā)育不全、腭裂和心臟異常為特征，RA已被證明對(duì)NCCs的形成至關(guān)重要[85,86]。RA攝入量的細(xì)微差異都將對(duì)NCCs的發(fā)展產(chǎn)生重大影響，孕期服用RA藥物會(huì)損害正常的顱面形態(tài)發(fā)生。過(guò)量的RA也會(huì)影響涉及顱骨發(fā)育的的表觀(guān)遺傳效應(yīng)。RA還被發(fā)現(xiàn)會(huì)導(dǎo)致小鼠的口腔–面部骨折，與兩個(gè)同源框基因2和表達(dá)異常相關(guān)[87]。此外，RA信號(hào)的改變可導(dǎo)致一種嚴(yán)重的致盲疾?。合忍煨郧喙庋踇88]?？梢钥隙ǖ氖荝A致畸的分子基礎(chǔ)是在胚胎期RA刺激p53過(guò)度激活，增加了NCCs的凋亡，導(dǎo)致顱骨、心臟甚至骶骨NCCs缺乏[89,90]。

3.3.3 煙霧：香煙、尼古丁、煙草、煙塵

抽煙(尼古丁)也是導(dǎo)致出生類(lèi)缺陷的重要風(fēng)險(xiǎn)因素，孕婦孕期接觸香煙會(huì)導(dǎo)致胎兒煙草綜合征(fetal tobacco syndrome，F(xiàn)TS)，除了呼吸異常和心臟缺陷外，F(xiàn)TS的主要特征是唇腭裂[91]。在非洲爪蟾胚胎和哺乳動(dòng)物NCCs中進(jìn)行的一項(xiàng)研究表明，尼古丁和霧化電子煙液的暴露會(huì)導(dǎo)致多種出生缺陷，包括正中面部裂隙和中面部發(fā)育不全[92]。胚胎暴露在香煙煙霧提取物(一種含有低水平的芳香烴受體(aromatic hydrocarbon receptor，AHR)配體化合物)中，主要通過(guò)下調(diào)Wnt信號(hào)通路的共激活因子R-spondin1影響Wnt通路，該通路是遷移性NCCs的關(guān)鍵信號(hào)[93]。皮膚中的所有細(xì)胞都表達(dá)AHR，如在黑素細(xì)胞、朗格漢斯細(xì)胞(langerhans cells，LCs)、表皮外層和成纖維細(xì)胞等[94]。因此長(zhǎng)期暴露在尼古丁下的胎兒，心臟、皮膚等發(fā)育都將受到影響。

3.3.4 葉酸(folic acid, FA)：甲氨蝶呤(metho-trexate, MTX)

葉酸對(duì)神經(jīng)嵴細(xì)胞的發(fā)育至關(guān)重要。在懷孕期，合理的葉酸補(bǔ)充可以防止神經(jīng)管缺陷、顱面畸形和心臟缺陷的發(fā)生[95]。此外，體外和體內(nèi)實(shí)驗(yàn)表明，葉酸水平的異常變化可導(dǎo)致雞心NCCs的異常遷移和分化。在早期的NCCs特化過(guò)程中，正常的口腔發(fā)育需要DHFR信號(hào)[96]。MTX是FA的拮抗劑，它競(jìng)爭(zhēng)性地抑制二氫葉酸還原酶(dihydrofolate reductase，DHFR)，導(dǎo)致葉酸的缺乏[96,97]。在雞胚實(shí)驗(yàn)中，MTX處理會(huì)促使兩種主要的葉酸轉(zhuǎn)運(yùn)蛋白FolR1和RFC1的下調(diào)，影響和的正常表達(dá)，擾亂了口腔面部組織的形成，推測(cè)葉酸可能參與了胎兒口面組織的發(fā)育[98]。

4 結(jié)語(yǔ)與展望

神經(jīng)嵴細(xì)胞對(duì)脊椎動(dòng)物頭部的“精細(xì)雕琢”賦予其進(jìn)化上的絕對(duì)優(yōu)勢(shì)。在人體內(nèi)，其形成了復(fù)雜有序的神經(jīng)系統(tǒng)與感觀(guān)系統(tǒng)，使人類(lèi)擁有強(qiáng)大的認(rèn)知和創(chuàng)造能力。然而，當(dāng)今人們對(duì)神經(jīng)嵴細(xì)胞的認(rèn)知依舊較淺，雖然現(xiàn)有研究對(duì)NCCs的形成、遷移和分化進(jìn)行了解析，并在組織和單細(xì)胞維度初步揭示了NCCs多能性機(jī)制、細(xì)胞命運(yùn)決定模式和發(fā)育進(jìn)程，但NCCs的發(fā)育和命運(yùn)如何被精準(zhǔn)調(diào)控、NCCs的遷移路線(xiàn)如何決定、NCCs和周?chē)?xì)胞的如何交互共分化、在時(shí)空層面NCCs如何被精準(zhǔn)調(diào)控以及基因突變影響了NCCs的哪個(gè)發(fā)育階段等科學(xué)問(wèn)題仍有待深入揭示。

由于神經(jīng)嵴細(xì)胞發(fā)育過(guò)程復(fù)雜，受到多種信號(hào)因子的調(diào)節(jié)，導(dǎo)致被擾亂的神經(jīng)嵴細(xì)胞與最終發(fā)生畸變的組織類(lèi)型之間匹配困難：即具有相同表型的NCPs可能是由不同NCCs類(lèi)型的不同發(fā)育過(guò)程被擾亂所引起，如先天性巨結(jié)腸既可由NCCs遷移異常也可由分化異常所導(dǎo)致[75]；不同表型的NCPs可能是由同一基因在NCCs不同發(fā)育階段的突變導(dǎo)致的，如SOX10的突變可以在NCCs遷移或分化中分別導(dǎo)致先天性巨結(jié)腸或WS[99]。因此神經(jīng)嵴病的癥狀具有較大的表型異質(zhì)性和病因同源性，這給研究NCCs發(fā)育過(guò)程和NCPs的致病機(jī)制帶來(lái)了嚴(yán)峻考驗(yàn)。精準(zhǔn)明晰NCPs的致病突變將有助于實(shí)施針對(duì)性的治療和預(yù)防手段[100]，在基因、蛋白和功能層面的在體外動(dòng)物實(shí)驗(yàn)有助于闡明NCPs的致病機(jī)制，并揭示關(guān)鍵治療靶點(diǎn)[101]。

隨著單細(xì)胞RNA測(cè)序的進(jìn)展，特別是單細(xì)胞多組學(xué)方法的快速發(fā)展，神經(jīng)嵴譜系中各類(lèi)細(xì)胞的形成節(jié)點(diǎn)和驅(qū)動(dòng)其多能性的機(jī)制也逐漸被解析。NCCs單細(xì)胞數(shù)據(jù)證實(shí)了之前對(duì)神經(jīng)嵴基因調(diào)控網(wǎng)絡(luò)的認(rèn)知，并且揭示了許多新的轉(zhuǎn)錄調(diào)控因子，并發(fā)現(xiàn)了新的調(diào)控網(wǎng)絡(luò)(迷走–神經(jīng)嵴調(diào)控網(wǎng)絡(luò))[102,103]。同時(shí)經(jīng)典的神經(jīng)胚層假說(shuō)也可以驗(yàn)證：即NCCs起源于神經(jīng)外胚層，具備分化為多種類(lèi)型細(xì)胞的多能性。最新研究揭示NCCs可被Oct4重編程恢復(fù)至囊胚期的多能性，進(jìn)而分化為其他胚層細(xì)胞[104]，從而推測(cè)NCCs不僅僅是“第四胚層”，其多能性甚至要高于內(nèi)、中和外胚層。Soldatov等[6]利用NCCs的單細(xì)胞數(shù)據(jù)發(fā)現(xiàn)NCCs的命運(yùn)似乎從遷移開(kāi)始前后就已經(jīng)被決定，NCCs的命運(yùn)決定有三個(gè)主要階段：(1)遷移前后的協(xié)同激活，(2)遷移過(guò)程中的命運(yùn)逐步偏倚和(3)遷移結(jié)束的分化階段不同的細(xì)胞決策。然而，單細(xì)胞方法不可避免地失去了空間/解剖位置的信息，空間組學(xué)的最新進(jìn)展將在不久的將來(lái)揭示神經(jīng)嵴細(xì)胞命運(yùn)如何在正確的時(shí)間和地點(diǎn)被激活以形成相應(yīng)的衍生物，為神經(jīng)嵴細(xì)胞的命運(yùn)和功能帶來(lái)新的認(rèn)知，為神經(jīng)嵴病的病因?qū)W揭示和疾病防控及治療提供關(guān)鍵技術(shù)。

附加材料見(jiàn)文章電子版wwww.chinagene.cn。

[1] Bae CJ, Saint-Jeannet JP. Induction and specification of neural crest cells: extracellular signals and transcriptional switches., 2014, 27–49.

[2] Martik ML, Gandhi S, Uy BR, Gillis JA, Green SA, Simoes-Costa M, Bronner ME. Evolution of the new head by gradual acquisition of neural crest regulatory circuits., 2019, 574(7780): 675–678.

[3] Martik ML, Bronner ME. Riding the crest to get a head: neural crest evolution in vertebrates., 2021, 22(10): 616–626.

[4] Hoppler S, Wheeler GN. DEVELOPMENTAL BIOLOGY. It's about time for neural crest., 2015, 348(6241): 1316–1317.

[5] Yuan Y, Loh YHE, Han X, Feng JF, Ho TV, He JZ, Jing JJ, Groff K, Wu AL, Chai Y. Spatiotemporal cellular movement and fate decisions during first pharyngeal arch morphogenesis., 2020, 6(51): eabb0119.

[6] Soldatov R, Kaucka M, Kastriti ME, Petersen J, Chontorotzea T, Englmaier L, Akkuratova N, Yang YS, H?ring M, Dyachuk V, Bock C, Farlik M, Piacentino ML, Boismoreau F, Hilscher MM, Yokota C, Qian XY, Nilsson M, Bronner ME, Croci L, Hsiao WY, Guertin DA, Brunet JF, Consalez GG, Ernfors P, Fried K, Kharchenko PV, Adameyko I. Spatiotemporal structure of cell fate decisions in murine neural crest., 2019, 364(6444): eaas9536.

[7] Zhu YL, Crowley SC, Latimer AJ, Lewis GM, Nash R, Kucenas S. Migratory neural crest cells phagocytose dead cells in the developing nervous system., 2019, 179(1): 74–89. e10.

[8] Le Douarin NM, Dupin E. The neural crest, a fourth germ layer of the vertebrate embryo: significance in chordate evolution., 2014, 3–26.

[9] Bolande RP. The neurocristopathies: A unifying concept of disease arising in neural crest maldevelopment., 1974, 5(4): 409–429.

[10] Trainor P, Krumlauf R, Bronner-Fraser M. 19 - Neural Crest Cells. In:Edited by Lanza R, Gearhart J, Hogan B, Melton D, Pedersen R, Thomson J, West M. Burlington: Academic Press, 2004, 219–232.

[11] Vega-Lopez GA, Cerrizuela S, Tribulo C, Aybar MJ. Neurocristopathies: New insights 150 years after the neural crest discovery., 2018, 444 (Suppl 1): S110–S143.

[12] Alkobtawi M, Pla P, Monsoro-Burq AH. BMP signaling is enhanced intracellularly by FHL3 controlling WNT- dependent spatiotemporal emergence of the neural crest., 2021, 35(12): 109289.

[13] Copeland J, Simoes-Costa M. Post-transcriptional tuning of FGF signaling mediates neural crest induction., 2020, 117(52): 33305–33316.

[14] Minoux M, Rijli FM. Molecular mechanisms of cranial neural crest cell migration and patterning in craniofacial development., 2010, 137(16): 2605–2621.

[15] Dyson Y, Holmes A, Li A, Kulesa PM. A chemotactic model of trunk neural crest cell migration., 2018, 56(9): e23239.

[16] Burns AJ, Le Douarin NM. Enteric nervous system development: analysis of the selective developmental potentialities of vagal and sacral neural crest cells using quail-chick chimeras., 2010, 262(1): 16–28.

[17] Szabó A, Mayor R. Mechanisms of neural crest migration., 2018, 52: 43–63.

[18] Sim?es-Costa M, Bronner ME. Insights into neural crest development and evolution from genomic analysis., 2013, 23(7): 1069–1080.

[19] Reed RJ. Cutaneous manifestations of neural crest disorders (neurocristopathies)., 1977, 16(10): 807–826.

[20] A Vega-Lopez G, J Aybar M. Neurocristopathies: how new discoveries in neural crest research changed our understanding., 2018, 7(2).

[21] Cordero DR, Brugmann S, Chu Y, Bajpai R, Jame M, Helms JA. Cranial neural crest cells on the move: their roles in craniofacial development., 2011, 155A(2): 270–279.

[22] Xu XP, Wang BQ, Jiang ZY, Chen Q, Mao K, Shi XF, Yan C, Hu JT, Zha Y, Ma C, Zhang J, Guo R, Wang LG, Zhao SQ, Liu HS, Zhang QG, Zhang YB. Novel risk factors for craniofacial microsomia and assessment of their utility in clinic diagnosis., 2021, 30(11): 1045– 1056.

[23] Zhang DC, Ighaniyan S, Stathopoulos L, Rollo B, Landman K, Hutson J, Newgreen D. The neural crest: a versatile organ system., 2014, 102(3): 275–298.

[24] Schulz Y, Wehner P, Opitz L, Salinas-Riester G, Bongers EMHF, van Ravenswaaij-Arts CMA, Wincent J, Schoumans J, Kohlhase J, Borchers A, Pauli S. CHD7, the gene mutated in CHARGE syndrome, regulates genes involved in neural crest cell guidance., 2014, 133(8): 997–1009.

[25] Mort RL, Jackson IJ, Patton EE. The melanocyte lineage in development and disease., 2015, 142(7): 1387.

[26] Kelberman D, Rizzoti K, Lovell-Badge R, Robinson ICAF, Dattani MT. Genetic regulation of pituitary gland development in human and mouse., 2009, 30(7): 790–829.

[27] Tortora C, Meazzini MC, Garattini G, Brusati R. Prevalence of abnormalities in dental structure, position, and eruption pattern in a population of unilateral and bilateral cleft lip and palate patients., 2008, 45(2): 154–162.

[28] Li X, Hu JT, Zhang J, Jin Q, Wang DM, Yu J, Zhang QG, Zhang YB. Genome-wide linkage study suggests a susceptibility locus for isolated bilateral microtia on 4p15. 32-4p16. 2., 2014, 9(7): e101152.

[29] Onwochei BC, Simon JW, Bateman JB, Couture KC, Mir E. Ocular colobomata., 2000, 45(3): 175–194.

[30] SooHoo JR, Davies BW, Allard FD, Durairaj VD. Congenital ptosis., 2014, 59(5): 483– 492.

[31] Jones NC, Lynn ML, Gaudenz K, Sakai D, Aoto K, Rey JP, Glynn EF, Ellington L, Du CY, Dixon J, Dixon MJ, Trainor PA. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function., 2008, 14(2): 125–133.

[32] Sakai D, Trainor PA. Face off against ROS: Tcof1/Treacle safeguards neuroepithelial cells and progenitor neural crest cells from oxidative stress during craniofacial development., 2016, 58(7): 577–585.

[33] Selleck MA, Bronner-Fraser M. Origins of the avian neural crest: the role of neural plate-epidermal interactions., 1995, 121(2): 525–538.

[34] Zhang YB, Hu JT, Zhang J, Zhou X, Li X, Gu CH, Liu T, Xie YC, Liu JQ, Gu ML, Wang PP, Wu TT, Qian J, Wang Y, Dong XQ, Yu J, Zhang QG. Genome-wide association study identifies multiple susceptibility loci for craniofacial microsomia., 2016, 7: 10605.

[35] Wilson DN, Doudna Cate JH. The structure and function of the eukaryotic ribosome., 2012, 4(5): a011536.

[36] Narla A, Hurst SN, Ebert BL. Ribosome defects in disorders of erythropoiesis., 2011, 93(2): 144-149.

[37] Selvi R, Mukunda PA. Role of SOX9 in the etiology of Pierre-Robin syndrome., 2013, 16(5): 700–704.

[38] Boudjadi S, Chatterjee B, Sun WY, Vemu P, Barr FG. The expression and function of PAX3 in development and disease., 2018, 666: 145–157.

[39] Li H, Sheridan R, Williams T. Analysis of TFAP2A mutations in Branchio-Oculo-Facial Syndrome indicates functional complexity within the AP-2α DNA-binding domain., 2013, 22(16): 3195–3206.

[40] Dixon J, Trainor PA, Dixon MJ. TCOF1 (treacle) and the treacher-collins syndrome. In: The Molecular Basis of Clinical Disorders of Morphogenesis. Oxford University Press. 2016.

[41] Dauwerse JG, Dixon J, Seland S, Ruivenkamp CAL, van Haeringen A, Hoefsloot LH, Peters DJM, Boers ACD, Daumer-Haas C, Maiwald R, Zweier C, Kerr B, Cobo AM, Toral JF, Hoogeboom AJM, Lohmann DR, Hehr U, Dixon MJ, Breuning MH, Wieczorek D. Mutations in genes encoding subunits of RNA polymerases I and III cause Treacher Collins syndrome., 2011, 43(1): 20–22.

[42] Engidaye G, Melku M, Enawgaw B. Diamond blackfan anemia: genetics, pathogenesis, diagnosis and treatment., 2019, 30(1): 67–81.

[43] Chang CF, Schock EN, Billmire DA, Brugmann SA. Craniofacial syndromes: etiology, impact and treatment. In: Principles of Developmental Genetics (Second Edition), 2015, 653–676.

[44] Cassina M, Cerqua C, Rossi S, Salviati L, Martini A, Clementi M, Trevisson E. A synonymous splicing mutation in the SF3B4 gene segregates in a family with highly variable Nager syndrome., 2017, 25(3): 371–375.

[45] Shi JL, Severson C, Yang JX, Wedlich D, Klymkowsky MW. Snail2 controls mesodermal BMP/Wnt induction of neural crest., 2011, 138(15): 3135–3145.

[46] Sánchez-Mejías A, Fernández RM, López-Alonso M, A?tinolo G, Borrego S. New roles of EDNRB and EDN3 in the pathogenesis of Hirschsprung disease., 2010, 12(1): 39–43.

[47] Fontanella B, Russolillo G, Meroni G. MID1 mutations in patients with X-linked Opitz G/BBB syndrome., 2008, 29(5): 584–594.

[48] Ghosh S, Li L, Tourtellotte WG. Retrograde nerve growth factor signaling abnormalities and the pathogenesis of familial dysautonomia., 2021, 16(9): 1795–1796.

[49] Bachetti T, Ceccherini I. Causative and common PHOX2B variants define a broad phenotypic spectrum., 2020, 97(1): 103–113.

[50] Lakhdar Y, El Houda HA, Mounji H, Elfakiri M, Rochdi Y, Moutaouakil A, Raji A. The Tietz syndrome associated with cardiac malformation: a case report with literature review.2021, 37(1): 112.

[51] Pingault V, Zerad L, Bertani-Torres W, Bondurand N. SOX10: 20 years of phenotypic plurality and current understanding of its developmental function., 2021, DOI: 10. 1136/jmedgenet-2021-108105.

[52] Agarwal S, Ojha A. Piebaldism: A brief report and review of the literature., 2012, 3(2): 144–147.

[53] Papakonstantinou E, Bacopoulou F, Brouzas D, Megalooikonomou V, D'Elia D, Bongcam-Rudloff E, Vlachakis D. NOTCH3 and CADASIL syndrome: a genetic and structural overview., 2019, 24: e921.

[54] Raivio T, Avbelj M, McCabe MJ, Romero CJ, Dwyer AA, Tommiska J, Sykiotis GP, Gregory LC, Diaczok D, Tziaferi V, Elting MW, Padidela R, Plummer L, Martin C, Feng B, Zhang CK, Zhou QY, Chen HB, Mohammadi M, Quinton R, Sidis Y, Radovick S, Dattani MT, Pitteloud N. Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia., 2012, 97(4): E694–E699.

[55] Chacon-Camacho OF, Fuerte-Flores BI, Zenteno JC. TP63 mutation in a patient with acro-dermo-ungual- lacrimal- tooth syndrome: additional evidence of molecular overlap of the ADULT and EEC syndromes., 2016, 170(6): 1635–1638.

[56] Baggiolini A, Varum S, Mateos JM, Bettosini D, John N, Bonalli M, Ziegler U, Dimou L, Clevers H, Furrer R, Sommer L. Premigratory and migratory neural crest cells are multipotent in vivo., 2015, 16(3): 314–322.

[57] Theveneau E, Mayor R. Neural crest cell migration: guidance, pathways, and cell–cell interactions., 2014, 73–88.

[58] Grill C, Bergsteinsdóttir K, Ogmundsdóttir MH, Pogenberg V, Schepsky A, Wilmanns M, Pingault V, Steingrímsson E. MITF mutations associated with pigment deficiency syndromes and melanoma have different effects on protein function., 2013, 22(21): 4357–4367.

[59] Strobl-Mazzulla PH, Bronner ME. Epigenetic regulation of neural crest cells., 2014, 89–100.

[60] Hu N, Strobl-Mazzulla P, Sauka-Spengler T, Bronner ME. DNA methyltransferase3A as a molecular switch mediating the neural tube-to-neural crest fate transition., 2012, 26(21): 2380–2385.

[61] Jin BL, Tao Q, Peng JR, Soo HM, Wu W, Ying JM, Fields CR, Delmas AL, Liu XF, Qiu JX, Robertson KD. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function., 2008, 17(5): 690–709.

[62] Yu C, Yao XM, Zhao JL, Wang P, Zhang Q, Zhao CJ, Yao SH, Wei YQ. Wolf-Hirschhorn syndrome candidate 1 (whsc1) functions as a tumor suppressor by governing cell differentiation., 2017, 19(8): 606–616.

[63] Kleefstra T, Brunner HG, Amiel J, Oudakker AR, Nillesen WM, Magee A, Geneviève D, Cormier-Daire V, van Esch H, Fryns JP, Hamel BCJ, Sistermans EA, de Vries BBA, van Bokhoven H. Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome., 2006, 79(2): 370–377.

[64] Shpargel KB, Starmer J, Wang CC, Ge K, Magnuson T. UTX-guided neural crest function underlies craniofacial features of Kabuki syndrome., 2017, 114(43): E9046– E9055.

[65] Ignatius MS, Moose HE, El-Hodiri HM, Henion PD. colgate/hdac1 repression of foxd3 expression is required to permit mitfa-dependent melanogenesis., 2008, 313(2): 568–583.

[66] Singh N, Trivedi CM, Lu MM, Mullican SE, Lazar MA, Epstein JA. Histone deacetylase 3 regulates smooth muscle differentiation in neural crest cells and development of the cardiac outflow tract., 2011, 109(11): 1240–1249.

[67] DeLaurier A, Nakamura Y, Braasch I, Khanna V, Kato H, Wakitani S, Postlethwait JH, Kimmel CB. Histone deacetylase-4 is required during early cranial neural crest development for generation of the zebrafish palatal skeleton., 2012, 12(1): 16.

[68] Haberland M, Mokalled MH, Montgomery RL, Olson EN. Epigenetic control of skull morphogenesis by histone deacetylase 8., 2009, 23(14): 1625–1630.

[69] Strobl-Mazzulla PH, Bronner ME. A PHD12-Snail2 repressive complex epigenetically mediates neural crest epithelial-to-mesenchymal transition., 2012, 198(6): 999–1010.

[70] Cox SG, Kim H, Garnett AT, Medeiros DM, An W, Crump JG. An essential role of variant histone H3. 3 for ectomesenchyme potential of the cranial neural crest., 2012, 8(9): e1002938.

[71] Yoshimura K, Kitagawa H, Fujiki R, Tanabe M, Takezawa S, Takada I, Yamaoka I, Yonezawa M, Kondo T, Furutani Y, Yagi H, Yoshinaga S, Masuda T, Fukuda T, Yamamoto Y, Ebihara K, Li DY, Matsuoka R, Takeuchi JK, Matsumoto T, Kato S. Distinct function of 2 chromatin remodeling complexes that share a common subunit, Williams syndrome transcription factor (WSTF)., 2009, 106(23): 9280–9285.

[72] Kosho T, Okamoto N, Coffin-Siris Syndrome International Collaborators. Genotype-phenotype correlation of Coffin- Siris syndrome caused by mutations in SMARCB1, SMARCA4, SMARCE1, and ARID1A., 2014, 166C(3): 262–275.

[73] Wang DY, Weng YJ, Guo SY, Qin WH, Ni JL, Yu L, Zhang YX, Zhao QS, Ben JJ, Ma JQ. MicroRNA-1 regulates NCC migration and differentiation by targeting sec63., 2019, 15(12): 2538–2547.

[74] Wei AY, Zhao PH, Xia JL, Wang Q, Du XH. MicroRNA- 23a is required for the migration and differentiation of cranial neural crest cells of zebrafish., 2017, 5(1): 7–13.

魏安瑤, 趙鵬輝, 夏景蘭, 王強(qiáng), 杜興華. microRNA- 23a調(diào)控斑馬魚(yú)顱神經(jīng)嵴細(xì)胞遷移和分化. 發(fā)育醫(yī)學(xué)電子雜志, 2017, 5(1): 7–13.

[75] Torroglosa A, Alves MM, Fernández RM, A?tinolo G, Hofstra RM, Borrego S. Epigenetics in ENS development and Hirschsprung disease., 2016, 417(2): 209–216.

[76] Eberhart JK, He XJ, Swartz ME, Yan YL, Song H, Boling TC, Kunerth AK, Walker MB, Kimmel CB, Postlethwait JH. MicroRNA Mirn140 modulates Pdgf signaling during palatogenesis., 2008, 40(3): 290–298.

[77] Gao S, Moreno M, Eliason S, Cao HJ, Li X, Yu WJ, Bidlack FB, Margolis HC, Baldini A, Amendt BA. TBX1 protein interactions and microRNA-96-5p regulation controls cell proliferation during craniofacial and dental development: implications for 22q11. 2 deletion syndrome., 2015, 24(8): 2330–2348.

[78] Itoh T, Nozawa Y, Akao Y. MicroRNA-141 and -200a are involved in bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less homeobox 5., 2009, 284(29): 19272–19279.

[79] Yan B, Liu B, Zhu CD, Li KL, Yue LJ, Zhao JL, Gong XL, Wang CH. MicroRNA regulation of skin pigmentation in fish., 2013, 126(Pt 15): 3401–3408.

[80] Sato TS, Handa A, Priya S, Watal P, Becker RM, Sato Y. Neurocristopathies: Enigmatic Appearances of Neural Crest Cell-derived Abnormalities., 2019, 39(7): 2085–2102.

[81] Cerrizuela S, Vega-Lopez GA, Aybar MJ. The role of teratogens in neural crest development., 2020, 112(8): 584–632.

[82] Fainsod A, Kot-Leibovich H. Xenopus embryos to study fetal alcohol syndrome, a model for environmental teratogenesis., 2018, 96(2): 77–87.

[83] Tolosa EJ, Fernández-Zapico ME, Battiato NL, Rovasio RA. Sonic hedgehog is a chemotactic neural crest cell guide that is perturbed by ethanol exposure., 2016, 95(3/5): 136–152.

[84] Flentke GR, Baulch JW, Berres ME, Garic A, Smith SM. Alcohol-mediated calcium signals dysregulate pro- survival Snai2/PUMA/Bcl2 networks to promote p53-mediated apoptosis in avian neural crest progenitors., 2019, 111(12): 686–699.

[85] Mulder GB, Manley N, Grant J, Schmidt K, Zeng W, Eckhoff C, Maggio-Price L. Effects of excess vitamin A on development of cranial neural crest-derived structures: a neonatal and embryologic study., 2000, 62(4): 214–226.

[86] Mondal D, Shenoy SR, Mishra S. Retinoic acid embryopathy., 2017, 7(4): 264–265.

[87] Zhao Y, Guo YJ, Tomac AC, Taylor NR, Grinberg A, Lee EJ, Huang S, Westphal H. Isolated cleft palate in mice with a targeted mutation of the LIM homeobox gene lhx8., 1999, 96(26): 15002–15006.

[88] Niederreither K, Dollé P. Retinoic acid in development: towards an integrated view., 2008, 9(7): 541–553.

[89] Melnik BC. Overexpression of p53 explains isotretinoin's teratogenicity., 2018, 27(1): 91–93.

[90] Melnik BC. Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity., 2017, 97(2): 173–181.

[91] Bronner ME, LeDouarin NM. Development and evolution of the neural crest: an overview., 2012, 366(1): 2–9.

[92] Kennedy AE, Kandalam S, Olivares-Navarrete R, Dickinson AJG. E-cigarette aerosol exposure can cause craniofacial defects in Xenopus laevis embryos and mammalian neural crest cells., 2017, 12(9): e0185729.

[93] Sanbe A, Mizutani R, Miyauchi N, Yamauchi J, Nagase T, Yamamura KI, Tanoue A. Inhibitory effects of cigarette smoke extract on neural crest migration occur through suppression of R-spondin1 expression via aryl hydrocarbon receptor., 2009, 380(6): 569–576.

[94] Esser C, Bargen I, Weighardt H, Haarmann-Stemmann T, Krutmann J. Functions of the aryl hydrocarbon receptor in the skin., 2013, 35(6): 677–691.

[95] Li JJ, Shi Y, Sun J, Zhang YF, Mao BY. Xenopus reduced folate carrier regulates neural crest development epigenetically., 2011, 6(11): e27198.

[96] Silveira AB, Laranjeira ABA, Rodrigues GOL, Leal PC, Cardoso BA, Barata JT, Yunes RA, Zanchin NIT, Brandalise SR, Yunes JA. PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia., 2015, 6(15): 13105–13118.

[97] Rajagopalan PTR, Zhang ZQ, McCourt L, Dwyer M, Benkovic SJ, Hammes GG. Interaction of dihydrofolate reductase with methotrexate: ensemble and single- molecule kinetics., 2002, 99(21): 13481–13486.

[98] Alata Jimenez N, Torres Pérez SA, Sánchez-Vásquez E, Fernandino JI, Strobl-Mazzulla PH. Folate deficiency prevents neural crest fate by disturbing the epigenetic Sox2 repression on the dorsal neural tube., 2018, 444 Suppl 1: S193–S201.

[99] Zhang H, Chen HS, Luo HJ, An J, Sun L, Mei LY, He CF, Jiang L, Jiang W, Xia K, Li JD, Feng Y. Functional analysis of Waardenburg syndrome- associated PAX3 and SOX10 mutations: report of a dominant-negative SOX10 mutation in Waardenburg syndrome type II., 2012, 131(3): 491–503.

[100] Chen Q, Zhao Y, Shen G, Dai J. Etiology and pathogenesis of hemifacial microsomia., 2018, 97(12): 1297–1305.

[101] Gouignard N, Andrieu C, Theveneau E. Neural crest delamination and migration: looking forward to the next 150 years., 2018, 56(6-7): e23107.

[102] Zalc A, Sinha R, Gulati GS, Wesche DJ, Daszczuk P, Swigut T, Weissman IL, Wysocka J. Reactivation of the pluripotency program precedes formation of the cranial neural crest., 2021, 371(6529): eabb4776.

[103] Morarach K, Mikhailova A, Knoflach V, Memic F, Kumar R, Li W, Ernfors P, Marklund U. Diversification of molecularly defined myenteric neuron classes revealed by single-cell RNA sequencing., 2021, 24(1): 34–46.

[104] Artinger KB, Monsoro-Burq AH. Neural crest multipotency and specification: power and limits of single cell transcriptomic approaches., 2021, 10: 38.

附圖1 NCPs分類(lèi)統(tǒng)計(jì)Venn圖

Supplementary Fig. 1 Venn chart of NCPs classification

根據(jù)受累神經(jīng)嵴細(xì)胞發(fā)育過(guò)程對(duì)神經(jīng)嵴病進(jìn)行分類(lèi)，重疊部分清楚地顯示了某些NCPs歸因于多個(gè)過(guò)程發(fā)育受阻。

Abbreviations of NCPs described in this article: TCS: Treacher Collins syndrome Treacher Collins綜合征；KS: Kallmann Syndrome Kallmann綜合征；PRS: Pierre Robin Sequence皮埃爾·羅賓序列；HPE: holoprosencephaly前腦無(wú)裂畸形；HH: hypogonadotropic hypogonadism 性腺功能減退癥；MBS: Moebius Syndrome莫比烏斯綜合征；3MC: 3MC Syndrome 3MC綜合征；ADULT: ADULT Syndrome ADULT綜合征；AEC: AEC Syndrome AEC綜合征；AS: Alagille Syndrome Alagille綜合征；BOR: Branchio-Oto-Renal Syndrome鰓-耳-腎綜合征；CADASIL: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy大腦常染色體顯性動(dòng)脈病變伴皮層下梗死和白質(zhì)腦??；CDHS: Craniofacial-Deafness-Hand Syndrome 顱面-耳聾-手綜合征；GCMN: Giant Congenital Melanocytic Nevi巨大先天性黑素細(xì)胞痣；NF1: Neurofibromatosis I Ⅰ型神經(jīng)纖維瘤；WS: Waardenburg syndrome瓦登伯格綜合征；CED: Cranioectodermal dysplasia/Sensenbrenner syndrome顱骨外胚層發(fā)育不良/Sensenbrenner綜合征；EEC3: EEC3 syndrome EEC3綜合征；EVC: Ellis-van Creveld syndrome軟骨外胚層發(fā)育不良；FASD: Fetal Alcohol Spectrum Disorder胎兒酒精譜系障礙；GDFD: Growth Retardation, Developmental Delay, and Facial Dysmorphism生長(zhǎng)遲緩，發(fā)育遲緩，面部畸形；HCS: Hajdu-Cheney Syndrome Hajdu-Cheney綜合征；FS: Klippel-Feil Syndrome先天性短頸綜合征；LMS: Limb-Mammary Syndrome四肢-乳腺綜合征；MFDA: Mandibulofacial Dysostosis with Alopecia頜面部發(fā)育不良伴脫發(fā)；MS: Multiple sclerosis多發(fā)性硬化癥；NAD: Nager Acrofacial Dysostosis Nager綜合征；NS: Noonan syndrome Noonan綜合征；PA: Peters Anomaly Peter異常/前段發(fā)育不良；PHACE: PHACE Syndrome PHACE綜合征；SAMS: SAMS disorder SAMS異常；SHFM4: Split-hand/split-foot malformation type 4裂手/裂腳畸形4型；TDO: Tricho-dento-osseous syndrome毛齒骨綜合征；22q11: 22q11.2 Deletion Syndrome (DGS) 22q11.2缺失綜合癥；AAA: Achalasia- Addisonianism-Alacrima Syndrome AAA綜合征；ACS: Auriculo Condylar Syndrome耳廓-髁狀突綜合征；ARS: Axenfeld- Rieger Syndrome Axenfeld-Rieger綜合征；BLS: Bamforth-Lazarus syndrome Bamforth-Lazarus綜合癥；BOFS: Branchio-Oculo-Facial Syndrome 鰓-眼-面部綜合征；BS: Binder Syndrome Binder綜合征；CCHS: Congenital Central Hypoventilation Syndrome先天性中樞性通氣不足綜合征；CHARGE: CHARGE syndrome CHARGE綜合征；CMT: Charcot-Marie-Tooth and Deafness Syndrome腓骨肌萎縮癥和耳聾綜合癥；CS: Craniosynostosis顱縫早閉；DBA: Diamond Blackfan Anemia先天性再生障礙性貧血；FD: Familial dysautonomia家族性自主神經(jīng)障礙；FMTC: Familial medullary thyroid carcinomas家族性甲狀腺髓樣癌；HFM: Hemifacial microsomia半側(cè)顏面短小.

Research progress on neural crest cells and neurocristopathies and its pathogenesis

Zhuoyuan Jiang1, Yan Zha1, Xiaofeng Shi3,4, Yongbiao Zhang2,3,4

Neural crest cells (NCCs) are multipotent progenitor cells unique to vertebrates, and they have the ability to differentiate into a variety of cells, such as chondrocytes, neurons, and melanocytes. The formation, migration, and differentiation of NCCs are tightly regulated, and the disruption of NCC development results in abnormal embryo development. Neurocristopathies (NCPs) refer to a group of diseases that develop in response to abnormal development of NCCs. NCPs are of various types and exhibit complex phenotypes, which can affect many parts of the human body, such as the craniofacial structure, heart, intestine, and skin. NCPs negatively impact the physical function and mental health of the affected patients. NCPs account for one third of the defects in children with birth defects. Genetic factors are the main risk factors for NCPs, but environmental factors and abnormal gene-environment interactions can also lead to the development of NCPs. In this review, we introduce NCCs, NCPs, and their pathogenesis, so as to provide a reference point for a systematic understanding of NCPs and NCC development, and to provide scientific support for understanding the etiology of NCPs and their effective prevention and control.

neural crest cells (NCCs); neurocristopathy; genetic regulation network; risk factors; pathogenesis

2021-09-29;

2021-12-11;

2022-01-04

國(guó)家自然科學(xué)基金(編號(hào)：82171844，81970898)和北京市自然科學(xué)基金(編號(hào)：7204273)資助[Supported by the National Natural Science Foundation of China (Nos. 82171844, 81970898) and Beijing Natural Science Foundation Project (No. 7204273)]

蔣卓遠(yuǎn)，在讀碩士研究生，專(zhuān)業(yè)方向：基礎(chǔ)醫(yī)學(xué)。E-mail: SY1910307@buaa.edu.cn

張永彪，博士，副研究員，研究方向：生物信息學(xué)。E-mail: zhangyongbiao@buaa.edu.cn

10.16288/j.yczz.21-253

(責(zé)任編委: 何淑君)